TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27692023

Group type: EXPERIMENTAL
Intervention: Red wine (150 ml with dinner)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mineral water (150 ml with dinner)
Number of subjects: 65
Study: 25313213

Group type: EXPERIMENTAL
Intervention: Rifampin Cmax >8.2 mg/liter
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pyrazinamide AUC/MIC >11.3
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rifampin AUC <35.4 mg · h/liter
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Isoniazid Cmax
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ethambutol Cmax/MIC
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Omitting isoniazid
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Increasing rifampin, pyrazinamide, and ethambutol exposures
Number of subjects: 54
Study: 24227358

Group type: EXPERIMENTAL
Intervention: Restricted fluid and salt regimen
Number of subjects: 240

Group type: COMPARATOR
Intervention: Liberal control fluid regimen
Number of subjects: 240
Study: 22147842

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 2515

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Number of subjects: 2515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2515
Study: 18923884

Group type: EXPERIMENTAL
Intervention: TPTD20 (20 microg)
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: TPTD40 (40 microg)
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study: 12772396

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba 100 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10884486

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWH)
Number of subjects: 3048
Study: 9292184

Group type: EXPERIMENTAL
Intervention: Budesonide 128 micrograms once daily
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Budesonide 256 micrograms once daily
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms once daily
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study: 8165608

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA and DHA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 20
Study: 3533454

Group type: EXPERIMENTAL
Intervention: Propafenone high dosage (300 mg every eight hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propafenone low dosage (150 mg every eight hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28410250

Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training (20 mins/d, 3 d/wk) together with traditional physical therapy for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 30
Study: 27715335

Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 744

Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY)
Number of subjects: 744

Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone (SFC)
Number of subjects: 744
Study: 24255993

Group type: EXPERIMENTAL
Intervention: 1‐h ultrasonic debridement with frequent oral hygiene reinforcement (OHI) over four visits
Number of subjects: 44

Group type: COMPARATOR
Intervention: 1‐h ultrasonic debridement without frequent oral hygiene reinforcement (control)
Number of subjects: 44
Study: 23025477

Group type: EXPERIMENTAL
Intervention: Revised QUOTE‐CNSLD instrument completed by parents at baseline (T0), after 1 year (T1), and after 2 years (T2)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Five-item 'child-specific' questionnaire about their caregiver, completed by children
Number of subjects: 107

Group type: COMPARATOR
Intervention: Quality of care in different follow-up settings (general practitioner, pediatrician, specialized asthma nurse)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Asthma-specific domain of the revised QUOTE‐CNSLD instrument
Number of subjects: 107

Group type: COMPARATOR
Intervention: Quality aspects derived from scores in all three study groups
Number of subjects: 107
Study: 19653573

Group type: EXPERIMENTAL
Intervention: Modafinil plus oral scopolamine (MS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modafinil plus placebo (MP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (DP)
Number of subjects: 60
Study: 17595750

Group type: EXPERIMENTAL
Intervention: Ranolazine in combination with standard anti-anginal medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard anti-anginal medications only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranolazine added to standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0
Study: 15154368

Group type: EXPERIMENTAL
Intervention: Bread made of bioactivated wheat grain
Number of subjects: 45
Study: 12002509

Group type: EXPERIMENTAL
Intervention: 32 mm cobalt‐chromium head
Number of subjects: 89

Group type: COMPARATOR
Intervention: 22 mm cobalt‐chromium head
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 10215735

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d., metronidazole 500 mg b.d., clarithromycin 500 mg b.d. for 1 week
Number of subjects: 50
Study: 7474331

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg once daily for 3 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 90
Study: 2081275

Group type: EXPERIMENTAL
Intervention: Bestatin 60 mg a day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7426081

Group type: EXPERIMENTAL
Intervention: Combined regimen of nicotinic acid (up to 3 g daily) and 2 g of clofibrate daily
Number of subjects: 555

Group type: COMPARATOR
Intervention: Control group on diet alone
Number of subjects: 555
Study: 31810006

Group type: EXPERIMENTAL
Intervention: Facility school attachment
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Facility school experience
Number of subjects: 569
Study: 31870345

Group type: EXPERIMENTAL
Intervention: Healthy Weight Programme (HWP)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: NHS intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: GYM intervention
Number of subjects: 76
Study: 28716236

Group type: EXPERIMENTAL
Intervention: Hypoglycemic treatment during hospitalization
Number of subjects: 3882

Group type: COMPARATOR
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 3882

Group type: COMPARATOR
Intervention: Diabetes mellitus (DM)
Number of subjects: 3882

Group type: COMPARATOR
Intervention: Normal fasting plasma glucose
Number of subjects: 3882

Group type: COMPARATOR
Intervention: No hypoglycemic treatment during hospitalization
Number of subjects: 3882
Study: 25811948

Group type: EXPERIMENTAL
Intervention: Caloric restriction with aerobic exercise (CR + EX)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Caloric restriction (CR)
Number of subjects: 70
Study: 24955812

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 22770894

Group type: EXPERIMENTAL
Intervention: Slow breathing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fast breathing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NFR (nociceptive flexion reflex)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HRV (heart rate variability)
Number of subjects: 30
Study: 19019048

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:80,000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:160,000
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lidocaine plain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline control
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:320,000
Number of subjects: 0
Study: 17564649

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral clonidine 4 µg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transmucosal dexmedetomidine 1 µg/kg
Number of subjects: 60
Study: 15151094

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 119

Group type: COMPARATOR
Intervention: Neodolpasse (75 mg diclofenac and 30 mg orphenadine)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 11903527

Group type: EXPERIMENTAL
Intervention: Botox A (500 MU)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 8
Study: 9486756

Group type: EXPERIMENTAL
Intervention: New SSRIs (fluvoxamine, paroxetine, sertraline)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (nonteratogenic agents)
Number of subjects: 267
Study: 7991322

Group type: EXPERIMENTAL
Intervention: Self-determination factors (self-confidence, positive attitude, listening skills, assuming responsibility)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Role models
Number of subjects: 40
Study: 2733675

Group type: EXPERIMENTAL
Intervention: Sanguinarine mouthrinses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwashes
Number of subjects: 0
Study: 30558852

Group type: EXPERIMENTAL
Intervention: PRE-RA arm (n=78)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: PRE-RA Plus arm (n=80)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Comparison arm (n=80)
Number of subjects: 238
Study: 27376466

Group type: EXPERIMENTAL
Intervention: TNF‐α inhibitors
Number of subjects: 0
Study: 26380439

Group type: EXPERIMENTAL
Intervention: Compound Tongtu Granule (CTG), 14.3 g per package, twice daily for 14 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, 14.3 g per package, twice daily for 14 days
Number of subjects: 80
Study: 23638621

Group type: EXPERIMENTAL
Intervention: Merional‐HG
Number of subjects: 157

Group type: COMPARATOR
Intervention: Menopur
Number of subjects: 157
Study: 22114973

Group type: EXPERIMENTAL
Intervention: exercise regime 'Hip School' (n = 70)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Non‐intervention control group (n = 70)
Number of subjects: 217

Group type: COMPARATOR
Intervention: 'Sham' ultrasound group (n = 70)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Ultrasound group (n = 7)
Number of subjects: 217
Study: 19170453

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback
Number of subjects: 295

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 295
Study: 16722029

Group type: EXPERIMENTAL
Intervention: New bicarbonate/lactate-buffered solution (N)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Gambrosol trio (GT)
Number of subjects: 13
Study: 15193680

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg/day
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 11768453

Group type: EXPERIMENTAL
Intervention: Surveillance system and collaborative interventions involving state and federal agencies, industry, labor, and professional organizations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative efforts to improve safety in helicopter lift operations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of surveillance data for action.
Number of subjects: 0
Study: 9247776

Group type: EXPERIMENTAL
Intervention: 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals), twice daily for 3 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo, twice daily for 3 months
Number of subjects: 49
Study: 7664425

Group type: EXPERIMENTAL
Intervention: Alpha 1-antagonist (prazosin)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alpha 2-antagonist (yohimbine)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both alpha 1 and alpha 2 antagonists
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (contralateral hand)
Number of subjects: 23
Study: 2655692

Group type: EXPERIMENTAL
Intervention: 125 micrograms of cyclopenthiazide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 500 micrograms of cyclopenthiazide
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 50 micrograms of cyclopenthiazide
Number of subjects: 53
Study: 359382

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meperidine hydrochloride
Number of subjects: 0
Study: 31813657

Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT) decompression
Number of subjects: 100

Group type: COMPARATOR
Intervention: No nasogastric tube (NGT) decompression
Number of subjects: 100
Study: 30654713

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 29
Study: 27369737

Group type: EXPERIMENTAL
Intervention: Training intervention starting at discharge and lasting three months, including exercises to increase range of motion and restore lung function and physical function.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 64
Study: 26682492

Group type: EXPERIMENTAL
Intervention: High accommodation by both parents
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High accommodation by one parent
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low accommodation by both parents
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High carer skills by both parents or mother alone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low carer skills by both parents
Number of subjects: 54
Study: 23824662

Group type: EXPERIMENTAL
Intervention: sugammadex 4 mg/kg
Number of subjects: 132

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: neostigmine 50 μg/kg/glycopyrrolate 10 μg/kg
Number of subjects: 132
Study: 21832216

Group type: EXPERIMENTAL
Intervention: Extended-release pramipexole (0.375-4.5 mg/day)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Immediate-release pramipexole (3 times daily)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 19410086

Group type: EXPERIMENTAL
Intervention: Mtwo rotary instruments with manual glide path (using #08-15 K files)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mtwo rotary instruments without manual glide path
Number of subjects: 40
Study: 17078576

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg administered 3 times/week (SCH)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Tadalafil 20 mg on demand (OD)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Preference for regimen
Number of subjects: 418
Study: 15599840

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11728654

Group type: EXPERIMENTAL
Intervention: Intervention group (multifaceted package including a workshop, written material, guidelines, and videos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 8908651

Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Estrogens
Number of subjects: 140
Study: 1895958

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (SRIF, 500 micrograms/h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SRIF infusion preceded by a nicotinic acid analogue (acipimox, 250 mg orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SRIF plus insulin infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SRIF plus insulin plus intralipid infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SRIF plus insulin infusion plus acipimox
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 6
Study: 6628507

Group type: EXPERIMENTAL
Intervention: triamterene 10 mg i.v.
Number of subjects: 6

Group type: COMPARATOR
Intervention: triamterene 50 mg p.o.
Number of subjects: 6
Study: 30762320

Group type: EXPERIMENTAL
Intervention: Right nostril intubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Left nostril intubation
Number of subjects: 40
Study: 27309418

Group type: EXPERIMENTAL
Intervention: 1.5 mm deep grafts
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.0 mm deep grafts
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.5 mm superficial grafts
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.0 mm superficial grafts
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Deep grafts
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Superficial grafts
Number of subjects: 33
Study: 26069949

Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (TIV)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 231
Study: 25123343

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Subsample of cannabis users
Number of subjects: 972
Study: 22919307

Group type: EXPERIMENTAL
Intervention: Tea‐flavor liquor (TFL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Traditional Chinese liquor (TCL)
Number of subjects: 45
Study: 19940820

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine at T9-L1 levels
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA) with 8 mg of 0.5% hyperbaric levobupivacaine at L2-L3 level
Number of subjects: 60
Study: 17633796

Group type: EXPERIMENTAL
Intervention: Spironolactone (group A) at a mean dose of 37.5 mg once a day (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No spironolactone (group B) (n = 14)
Number of subjects: 28
Study: 15122957

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA; 100 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12366874

Group type: EXPERIMENTAL
Intervention: Temporal coherence measures of sleep EEG rhythms
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard sleep measures
Number of subjects: 47
Study: 9667268

Group type: EXPERIMENTAL
Intervention: Myeloablative chemotherapy with autologous bone marrow rescue (ABMR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Myeloablative chemotherapy with ABMR followed by external-beam irradiation
Number of subjects: 20
Study: 7713852

Group type: EXPERIMENTAL
Intervention: Immediate switch to 20 mg of paroxetine daily after last dose of fluoxetine (N = 123)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo-washout followed by 20 mg of paroxetine daily (N = 119)
Number of subjects: 242
Study: 1693474

Group type: EXPERIMENTAL
Intervention: Dicumarol (coumarin derivative) orally postoperatively
Number of subjects: 116

Group type: COMPARATOR
Intervention: Heparin (postoperative treatment for all patients)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Critical ischemia
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Femoro‐distal reconstructions
Number of subjects: 116
Study: 111467

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30506981

Group type: EXPERIMENTAL
Intervention: EDAPTS plus TAU
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 96
Study: 27926575

Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 50
Study: 25088921

Group type: EXPERIMENTAL
Intervention: High-resolution white-light endoscopy (HR-WLE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of HR-WLE and NBI
Number of subjects: 52
Study: 24114718

Group type: EXPERIMENTAL
Intervention: Start For Life treatment (30 min per day)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Start For Life treatment
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care condition (30 min per day)
Number of subjects: 306
Study: 21527516

Group type: EXPERIMENTAL
Intervention: Unrelated double umbilical cord blood (dUCB) transplantation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical related donor bone marrow (Haplo-marrow) transplantation
Number of subjects: 100
Study: 19626381

Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy during PACU stay
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 60
Study: 17357049

Group type: EXPERIMENTAL
Intervention: Intranasal administration of citrate/phosphate (CP) buffer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 15529558

Group type: EXPERIMENTAL
Intervention: Low-energy transvenous internal cardioversion (ICV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transthoracic cardioversion (TT)
Number of subjects: 52
Study: 11176554

Group type: EXPERIMENTAL
Intervention: Inpatient programs that shortened their average length of stay
Number of subjects: 6397

Group type: EXPERIMENTAL
Intervention: Inpatient programs that converted to residential treatment
Number of subjects: 6397

Group type: EXPERIMENTAL
Intervention: Residential treatment programs established before the period of change
Number of subjects: 6397

Group type: COMPARATOR
Intervention: Inpatient PTSD programs that did not experience program change
Number of subjects: 6397
Study: 9141935

Group type: EXPERIMENTAL
Intervention: LA‐IVRA (90 mg of lysine acetylsalicylate mixed with prilocaine 0.5%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LA‐IV (1 mL of 0.9% NaCl mixed with prilocaine and 90 mg of LA administered IV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1 mL of 0.9% NaCl administered with prilocaine for IVRA and IV)
Number of subjects: 60
Study: 7895787

Group type: EXPERIMENTAL
Intervention: Patients with left FEF lesions
Number of subjects: 15